Gemina Laboratories Ltd
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporat… Read more
Gemina Laboratories Ltd (GLABF) - Net Assets
Latest net assets as of January 2025: $-4.44 Million USD
Based on the latest financial reports, Gemina Laboratories Ltd (GLABF) has net assets worth $-4.44 Million USD as of January 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.44 Million) and total liabilities ($5.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.44 Million |
| % of Total Assets | -308.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 298.94 |
Gemina Laboratories Ltd - Net Assets Trend (2021–2025)
This chart illustrates how Gemina Laboratories Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gemina Laboratories Ltd (2021–2025)
The table below shows the annual net assets of Gemina Laboratories Ltd from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-01-31 | $-4.44 Million | -179.78% |
| 2024-01-31 | $-1.59 Million | -2107.45% |
| 2023-01-31 | $-71.81K | -107.61% |
| 2022-01-31 | $944.23K | +490.28% |
| 2021-01-31 | $159.96K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gemina Laboratories Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2000438700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $16.40 Million | % |
| Total Equity | $-4.44 Million | 100.00% |
Gemina Laboratories Ltd Competitors by Market Cap
The table below lists competitors of Gemina Laboratories Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Electrocore LLC
NASDAQ:ECOR
|
$34.30 Million |
|
Silver One Resources Inc
OTCQX:SLVRF
|
$34.30 Million |
|
Sotherly Hotels Inc
NASDAQ:SOHO
|
$34.31 Million |
|
Sernova Corp
OTCQB:SEOVF
|
$34.31 Million |
|
Medicalg
WAR:MDG
|
$34.29 Million |
|
Archer Materials Limited
PINK:ARRXF
|
$34.27 Million |
|
YAS Co., Ltd.
KQ:255440
|
$34.26 Million |
|
Top High Image
TWO:3284
|
$34.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gemina Laboratories Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,585,194 to -4,435,079, a change of -2,849,885.
- Net loss of 4,073,658 reduced equity.
- Other comprehensive income decreased equity by 3,938,916.
- Other factors increased equity by 5,162,689.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.07 Million | -91.85% |
| Other Comprehensive Income | $-3.94 Million | -88.81% |
| Other Changes | $5.16 Million | +116.41% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Gemina Laboratories Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-01-31 | $0.00 | $0.79 | x |
| 2022-01-31 | $0.02 | $0.79 | x |
| 2023-01-31 | $0.00 | $0.79 | x |
| 2024-01-31 | $-0.02 | $0.79 | x |
| 2025-01-31 | $-0.06 | $0.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gemina Laboratories Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-204.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -521.47% | 0.00% | 0.00x | 15.80x | $-850.15K |
| 2022 | -501.46% | 0.00% | 0.00x | 1.50x | $-4.83 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.97 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.06 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.63 Million |
Industry Comparison
This section compares Gemina Laboratories Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gemina Laboratories Ltd (GLABF) | $-4.44 Million | -521.47% | N/A | $34.29 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |